Compass Therapeutics (CMPX)

R&D Expense Growth

46.36%

Quarterly · Period ending:

CMPX logo

CMPX R&D Expense Growth

Latest reported46.36%
CMPX Quarterly R&D Growth (QoQ) (0.00% → 46.36%)
High-resolution chart · PNG

CMPX r&d expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Compass Therapeutics R&D Expense Growth — Quarterly
Period endingR&D Expense Growth
46.3626%
-2.1866%
6.6116%
-21.8641%
25.7469%
0.1227%
51.3934%
-22.9282%
17.3493%
-23.3704%
40.7089%
-13.6164%
54.0072%
-33.1386%
1.3992%
67.0249%
32.7746%
-53.8855%
203.551%
8.5714%
-38.244%
6.7635%
20.0545%
22.9481%
-16.41%
8.1138%
-44.7566%
10.9482%
-25.5971%
0%
0%
0%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.